Covid: India's first mRNA vaccine under final trials, says govt

Indian Council of Medical Research Director General, Dr Balram Bhargava, said that this is another vaccine which really establishes that India is heading towards becoming a vaccine superpower

vaccination
Representative picture.
IANS New Delhi
2 min read Last Updated : Feb 10 2022 | 6:55 PM IST

India's first homegrown Messenger RNA (mRNA) Covid19 vaccine, being developed by Pune-based Gennova Biopharmaceuticals, is currently under final clinical trials, NITI Aayog's Member, Health, Dr V.K. Paul, said on Thursday.

Briefing the media, he said that they are hopeful that they will be able to use this vaccine soon.

"We need mRNA platform because it has shown that vaccines developed on this platform, at least for Covid-19, have been effective worldwide," said Paul, adding that beyond Covid, this platform will continue to be important as an option for future for other diseases also for which vaccines have been elusive. He termed it as an great development.

Indian Council of Medical Research Director General, Dr Balram Bhargava, said that this is another vaccine which really establishes that India is heading towards becoming a vaccine superpower.

"Because large parts of the population are vaccinated, we are not seeing the disastrous third Covid surge in terms of hospitalisations and mortality," he said.

About the ongoing pandemic situation, Dr Paul said that the world had learned a great deal about pandemic and the virus, but doesn't know everything.

The world should remain united to fight this virus and should continue to use the tools that are at our disposal, he added.

"Some states including Kerala, Mizoram, Himachal Pradesh are still reporting a large number of cases. We cannot lower our guard," he said

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusOmicronCoronavirus VaccineVaccineCoronavirus Tests

First Published: Feb 10 2022 | 6:55 PM IST

Next Story